المؤلفون: Mohamed T. Abuelazm, Abdelrahman Attia, Mohamed Abdelnabi, Uzair Jafar, Omar Almaadawy, Mohamed A. Elzeftawy, Abdelrahman Mahmoud, Khaled Albakri, Basel Abdelazeem

المصدر: The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-14 (2024)

مصطلحات موضوعية: Soluble guanylate cyclase stimulators, sGC stimulator, Heart failure, Riociguat, Vericiguat, Review, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2090-911X

URL الوصول: https://doaj.org/article/7b91382894ce43b2877eb91aa1437323

المؤلفون: Khanna, Dinesh, Kramer, Frank, Höfler, Josef, Ghadessi, Mercedeh, Sandner, Peter, Allanore, Yannick, Denton, Christopher P., Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E., Atsumi, Tatsuya, Bečvář, Radim, Czirják, Lászlo, de Langhe, Ellen, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R., Riccieri, Valeria, Schiopu, Elena, Silver, Richard M., Smith, Vanessa, Stagnaro, Chiara, Steen, Virginia, Stevens, Wendy, Szücs, Gabriella, Truchetet, Marie-Elise, Wosnitza, Melanie, Distler, Oliver

المساهمون: Université Paris Descartes - Paris 5 (UPD5), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)

المصدر: ISSN: 1462-0324.

مصطلحات موضوعية: biomarkers, diffuse cutaneous systemic sclerosis, riociguat, soluble guanylate cyclase stimulators, [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/38460548; PUBMED: 38460548

الاتاحة: https://hal.univ-lille.fr/hal-04679380
https://hal.univ-lille.fr/hal-04679380v1/document
https://hal.univ-lille.fr/hal-04679380v1/file/keae150.pdf
https://doi.org/10.1093/rheumatology/keae150

المؤلفون: Qinan Yin, Xingyue Zheng, Yujie Song, Liuyun Wu, Lian Li, Rongsheng Tong, Lizhu Han, Yuan Bian

المصدر: Frontiers in Pharmacology, Vol 14 (2023)

مصطلحات موضوعية: soluble guanylate cyclase stimulators, soluble guanylate cyclase activators, guanylate cyclase-c agonists, mechanism, signaling pathway, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2023.1272073/full; https://doaj.org/toc/1663-9812

URL الوصول: https://doaj.org/article/84e645a69eac4d22b972d8b00f5e9689

المؤلفون: Andersson, Karl Erik

المصدر: Expert Opinion on Therapeutic Targets. 28(4):251-258

مصطلحات موضوعية: antifibrosis, detrusor overactivity, Lower urinary tract symptoms, MaxiK±channels, overactive bladder syndrome, oxidative stress, P2X3 receptors, soluble guanylate cyclase stimulators, TRP channels, Medicin och hälsovetenskap, Medicinska och farmaceutiska grundvetenskaper, Farmakologi och toxikologi, Medical and Health Sciences, Basic Medicine, Pharmacology and Toxicology

URL الوصول: https://lup.lub.lu.se/record/e719c4e0-0047-4d1a-9873-d129bd3189fb
http://dx.doi.org/10.1080/14728222.2024.2344698

المؤلفون: Salvador, Mariana Isabel Cavaco

مصطلحات موضوعية: Inibidores da fosfodiesterase-5, Estimuladores da guanilato ciclase solúvel, Meta-análise, Insuficiência cardíaca de fração de ejeção reduzida, Heart failure reduced ejection fraction, Phosphodiesterase-5 inhibitors, Soluble guanylate cyclase stimulators, Meta-analysis

الاتاحة: https://hdl.handle.net/10316/102305

المؤلفون: Kassis-George H, Verlinden NJ, Fu S, Kanwar M

المصدر: Therapeutics and Clinical Risk Management, Vol Volume 18, Pp 315-322 (2022)

مصطلحات موضوعية: vericiguat, soluble guanylate cyclase stimulators, heart failure with reduced ejection fraction, guideline-directed medical therapy, victoria, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.dovepress.com/vericiguat-in-heart-failure-with-a-reduced-ejection-fraction-patient-s-peer-reviewed-fulltext-article-TCRM; https://doaj.org/toc/1178-203X

URL الوصول: https://doaj.org/article/94bd1c31094547a09aa6712d88db3ba6

المؤلفون: V. V. Bykov, A. V. Bykova, S. A. Stankevich, O. I. Aliev, A. V. Sidekhmenova, O. I. Dunaeva, V. A. Khazanov, A. I. Vengerovskii, V. V. Udut, В. В. Быков, А. В. Быкова, С. А. Станкевич, О. И. Алиев, А. В. Сидехменова, О. И. Дунаева, В. А. Хазанов, А. И. Венгеровский, В. В. Удут

المصدر: Bulletin of Siberian Medicine; Том 22, № 1 (2023); 14-22 ; Бюллетень сибирской медицины; Том 22, № 1 (2023); 14-22 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2023-22-1

مصطلحات موضوعية: риоцигуат, soluble guanylate cyclase stimulators, indolinone derivative GRS, riociguat, стимуляторы растворимой гуанилатциклазы, производное индолинона GRS

وصف الملف: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5127/3364; Humbert M., Guignabert C., Bonnet S., Dorfmüller P., Klinger J.R., Nicolls M.R. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019;53(1):1801887. DOI:10.1183/13993003.01887-2018.; Thenappan T., Ormiston M.L., Ryan J.J., Archer S.L. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. DOI:10.1136/bmj.j5492.; Hamilos M., Petousis S., Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc. Diagn. Ther. 2018;8(5):568–580. DOI:10.21037/cdt.2018.07.01.; Makhoul S., Walter E., Pagel O., Walter U., Sickmann A., Gambaryan S. et al. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. Nitric Oxide. 2018;76:71–80. DOI:10.1016/j.niox.2018.03.008.; Khaybullina D., Patel A., Zerilli T. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P.T. 2014;39(11):749–758.; Быков В.В., Чернышева Г.А., Смольякова В.И., Серебров В.Ю., Хазанов В.А., Удут В.В. Антиагрегантная активность нового производного индолинона. Экспериментальная и клиническая фармакология. 2019;82(7):10–13. DOI:10.30906/0869-2092-2019-82-7-10-13.; Bykov V.V., Smol’yakova V.I., Chernysheva G.A., Aliev O.I., Anishchenko A.M., Sidekhmenova A.V. et al. Effects of a new antithrombotic drug GRS, a soluble guanylate cyclase stimulator, on endothelial dysfunction in rats with myocardial infarction. Bull. Exp. Biol. Med. 2022;172(6):709–712. DOI:10.1007/s10517-022-05461-y.; Thomas H.C., Lamé M.W., Dunston S.K., Segall H.J., Wilson D.W. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol. Appl. Pharmacol. 1998;151(2):236–244. DOI:10.1006/taap.1998.8458.; Dumitrascu R., Koebrich S., Dony E., Weissmann N., Savai R., Pullamsetti S.S. et al. Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm. Med. 2008;8:25. DOI:10.1186/1471-2466-8-25.; Xiao R., Su Y., Feng T., Sun M., Liu B., Zhang J. et al. monocrotaline induces endothelial injury and pulmonary hypertension by targeting the extracellular calcium-sensing receptor. J. Am. Heart. Assoc. 2017;6(4):e004865. DOI:10.1161/JAHA.116.004865.; Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L. et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care. Med. 2004;169(1):39–45. DOI:10.1164/rccm.200302-282OC.; Сидехменова А.В., Алиев О.И., Анищенко А.М., Шаманаев А.Ю., Федорова Е.П., Плотников М.Б. Динамика показателей тромбоцитов, лейкоцитов и функциональной активности эндотелия у молодых крыс линии SHR. Сибирский журнал клинической и экспериментальной медицины. 2015;30(3):61–50. DOI:10.29001/2073-8552-201530-3-61-65.; Галаган М.Е., Широколова А.В., Ванин А.Ф. Гипотензивное действие оксида азота, продуцируемого из экзои эндогенных источников. Вопросы медицинской химии. 1991;37(1):67–70.; Покровский М.В., Кочкаров В.И., Покровская Т.Г., Гладченко М.П., Артюшкова Е.Б., Пашин Е.Н. и др. Методические подходы для количественной оценки развития эндотелиальной дисфункции при LNAME-индуцированной модели дефицита оксида азота в эксперименте. Кубанский научный медицинский вестник. 2006;10:72–77.; Hessel M.H., Steendijk P., den Adel B., Schutte C.I., van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am. J. Physiol. Heart. Circ. Physiol. 2006;291(5):H2424– 430. DOI:10.1152/ajpheart.00369.2006.; Prisco S.Z., Eklund M., Moutsoglou D.M., Prisco A.R., Khoruts A., Weir E.K. et al. Intermittent fasting enhances right ventricular function in preclinical pulmonary arterial hypertension. J. Am. Heart. Assoc. 2021;10(22):e022722. DOI:10.1161/JAHA.121.022722.; Sztuka K., Jasińska-Stroschein M. Animal models of pulmonary arterial hypertension: A systematic review and meta-analysis of data from 6126 animals. Pharmacol. Res. 2017;125(Pt B):201–214. DOI:10.1016/j.phrs.2017.08.003.; Авдеев С.Н., Барбараш О.Л., Баутин А.Е., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С. и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(12):4683. DOI:10.15829/1560-4071-2021-4683.; Kay J.M., Keane P.M., Suyama K.L., Gauthier D. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax. 1982;37(2):88–96. DOI:10.1136/thx.37.2.88.; Sandner P., Zimmer D.P., Milne G.T., Follmann M., Hobbs A., Stasch J.P. Soluble guanylate cyclase stimulators and activators. Handb. Exp. Pharmacol. 2021;264:355–394. DOI:10.1007/164_2018_197.; Hoeper M.M., Ghofrani H.A., Grünig E., Klose H., Olschewski H., Rosenkranz S. Pulmonary hypertension. Dtsch. Arztebl. Int. 2017;114(5):73–84. DOI:10.3238/arztebl.2017.0073.; Klinger J.R., Elliott C.G., Levine D.J., Bossone E., Duvall L., Fagan K. et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565–586. DOI:10.1016/j.chest.2018.11.030.; Ghofrani H.A., Grimminger F., Grünig E., Huang Y., Jansa P., Jing Z.C. et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 2016;4(5):361–771. DOI:10.1016/S2213-2600(16)30019-4.; https://bulletin.ssmu.ru/jour/article/view/5127

الاتاحة: https://bulletin.ssmu.ru/jour/article/view/5127
https://doi.org/10.20538/1682-0363-2023-1-14-22

المؤلفون: Xiao-Yan Jia, Yong-Ming Liu, Yong-Fei Wang, Jin-Yang An, Ke-Ling Peng, Hua Wang

المصدر: Frontiers in Pharmacology, Vol 13 (2022)

مصطلحات موضوعية: cardiovascular research, CiteSpace, bibliometrics, heart failure, soluble guanylate cyclase stimulators, web of science, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.963255/full; https://doaj.org/toc/1663-9812

URL الوصول: https://doaj.org/article/47876f9f100d4fe790e4cc93b536795d

المؤلفون: Humbert, M., Kovacs, G., Hoeper, M., Noi, A., Vataman, E.B.

المصدر: European Heart Journal 3618-3731

مصطلحات موضوعية: Balloon pulmonary angioplasty, Chronic thrombo-embolic pulmonary hypertension, congenital heart disease, connective tissue disease, Endothelin Receptor Antagonists, Guidelines, Left heart disease, lung disease, Lung transplantation, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Prostacyclin receptor agonists, Pulmonary arterial hypertension, Pulmonary endarterectomy, pulmonary hypertension, Soluble guanylate cyclase stimulators

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/182659; urn:issn:0195668X

الاتاحة: https://ibn.idsi.md/vizualizare_articol/182659
https://doi.org/10.1093/eurheartj/ehac237

المؤلفون: Butler, Javed, Usman, Muhammad Shariq, Anstrom, Kevin J., Blaustein, Robert O., Bonaca, Marc P., Ezekowitz, Justin A., Freitas, Cecilia, Lam, Carolyn S.P., Lewis, Eldrin F., Lindenfeld, Jo Ann, McMullan, Ciaran J., Mentz, Robert J., O'Connor, Christopher, Rosano, Giuseppe M.C., Saldarriaga, Clara Inés, Senni, Michele, Udelson, James, Voors, Adriaan A., Zannad, Faiez

المصدر: Butler , J , Usman , M S , Anstrom , K J , Blaustein , R O , Bonaca , M P , Ezekowitz , J A , Freitas , C , Lam , C S P , Lewis , E F , Lindenfeld , J A , McMullan , C J , Mentz , R J , O'Connor , C , Rosano , G M C , Saldarriaga , C I , Senni , M , Udelson , J , Voors , A A & Zannad , F 2022 , ' Soluble guanylate cyclase stimulators in patients ....

مصطلحات موضوعية: HFrEF, Soluble guanylate cyclase stimulators, Vericiguat

وصف الملف: application/pdf

الاتاحة: https://hdl.handle.net/11370/680949ed-3dde-4612-9df1-9e847c10cd3f
https://research.rug.nl/en/publications/680949ed-3dde-4612-9df1-9e847c10cd3f
https://doi.org/10.1002/ejhf.2720
https://pure.rug.nl/ws/files/258421413/European_J_of_Heart_Fail_2022_Butler_Soluble_guanylate_cyclase_stimulators_in_patients_with_heart_failure_with.pdf

المؤلفون: Khanna, D., Kramer, F., Höfler, J., Ghadessi, M., Sandner, P., Allanore, Y., Denton, C. P., Kuwana, M., Matucci-Cerinic, M., Pope, J. E., Atsumi, T., Bečvář, R., Czirják, L., De Langhe, E., Hachulla, Eric, Ishii, T., Ishikawa, O., Johnson, S. R., Riccieri, V., Schiopu, E., Silver, R. M., Smith, V., Stagnaro, C., Steen, V., Stevens, W., Szücs, G., Truchetet, M. E., Wosnitza, M., Distler, O.

المساهمون: Université de Lille, Inserm, CHU Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

مصطلحات موضوعية: biomarkers, diffuse cutaneous systemic sclerosis, riociguat, soluble guanylate cyclase stimulators

Relation: Rheumatology (Oxford); http://hdl.handle.net/20.500.12210/114111

الاتاحة: https://hdl.handle.net/20.500.12210/114111

المؤلفون: A A Shmalts, S V Gorbachevsky

المصدر: Системные гипертензии, Vol 15, Iss 2, Pp 72-76 (2018)

مصطلحات موضوعية: pulmonary arterial hypertension, pah-specific therapy, soluble guanylate cyclase stimulators, phosphodiesterase-5 inhibitors, nitrogen oxide, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://syst-hypertension.ru/2075-082X/article/viewFile/29613/pdf; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/435598fd84da491aa1f110b65385f91a

المؤلفون: Shmalts А.А., Gorbachevsky S.V.

المصدر: Системные гипертензии, Vol 15, Iss 2, Pp 72-76 (2018)

مصطلحات موضوعية: pulmonary arterial hypertension, PAH-specific therapy, soluble guanylate cyclase stimulators, phosphodiesterase-5 inhibitors, nitrogen oxide, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: http://www.syst-hypertension.ru/en/archive/2018/vol-15-2-2018/nitrogen-oxide-biochemical-pathway-in-pulmonary-arterial-hypertension-therapy-and-replace-trial-resu_1891/; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/e05252e4aeb34859ad0f3c2804e4301f

المصدر: European Journal of Heart Failure. 24(11):2029-2036

مصطلحات موضوعية: Vericiguat, HFrEF, Soluble guanylate cyclase stimulators

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dris___01423::b60c99ecc37bdd7894825f77d067e384
https://research.rug.nl/en/publications/680949ed-3dde-4612-9df1-9e847c10cd3f

المؤلفون: Norris S. H. Lan, Benjamin D. Massam, Sandeep S. Kulkarni, Chim C. Lang

المصدر: Diseases; Volume 6; Issue 2; Pages: 38

مصطلحات موضوعية: pulmonary arterial hypertension, nitric oxide, prostacyclin-thromboxane, endothelin-1, phosphodiesterase-5 inhibitor, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists, endothelin receptor antagonists, mortality

وصف الملف: application/pdf

Relation: Cardiology; https://dx.doi.org/10.3390/diseases6020038

الاتاحة: https://doi.org/10.3390/diseases6020038

المؤلفون: K. I. Ivanov, К. И. Иванов

المصدر: PULMONOLOGIYA; Том 27, № 6 (2017); 803-810 ; Пульмонология; Том 27, № 6 (2017); 803-810 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-27-6

مصطلحات موضوعية: риоцигуат, soluble guanylate cyclase stimulators, riociguat, стимуляторы растворимой гуанилатциклазы

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/948/796; Nazzareno G., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J. 2016; 37 (1): 67–119. DOI:10.1093/eurheartj/ehv317.; Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Актуальные вопросы современной комбинированной специфической терапии легочной артериальной гипертензии: за и против. Медицинский совет. 2017; (5): 10–18. DOI:10.21518/2079-701X-2017-5-10-18.; McLaughlin V., Channik R.N., Ghofrani H.A. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur. Respir. J. 2015; 46 (2): 405–413. DOI:10.1183/13993003.02044-2014.; Taichman D.B., Ornelas J., Chung L. et al. Pharmacologic therapy for pulmonary arterial hypertension in adults. CHEST guideline and expert panel report. Chest. 2014; 146 (2): 449–475 DOI:10.1378/chest.14-0793.; Liu H.L., Chen X.Y., Li J.R. et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Chest. 2016; 150 (2): 353–366. DOI:10.1016/j.chest.2016.03.031.; Hoeper M.M., Benza R., Simonneau G. et al. Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i). Eur. Respir. J. 2015; 46 (Suppl. 59): PA2110. DOI:10.1183/13993003.congress-2015.PA2110.; O’Callaghan D.S., Savale L., Montani D. et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat. Rev. Cardiol. 2011; 8 (9): 526–538. DOI:10.1038/nrcardio.2011.104.; Wilkins M.R. Pulmonary hypertension: the science behind the disease spectrum. Eur. Respir. Rev. 2012; 21 (123): 19–26. DOI:10.1183/09059180.00008411.; Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016: 26 (1): 85–91. DOI:10.18093/0869-0189-2016-26-1-85-91.; Evgenov O.V., Pacher P., Schmidt P.M. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 2006; 5 (9): 755–768. DOI:10.1038/nrd2038.; Ghofrani H.-A., Voswinckel R., Gall H. et al. Riociguat for pulmonary hypertension. Future Cardiol. 2010; 6 (2): 155–166. DOI:10.2217/fca.10.5.; Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995; 333 (4): 214–221. DOI:10.1056/NEJM199507273330403.; Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011; 123 (20): 2263–2273. DOI:10.1161/CIRCULATIONAHA.110.981738.; Ghofrani H.A., Galiè N., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369 (4): 330–340. DOI:10.1056/NEJMoa1209655.; Rubin L.J., Galiè N., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur. Respir. J. 2015; 45 (5): 1303–1313. DOI:10.1183/09031936.00090614.; Ghofrani H.A., Grimminger F., Grunig E. et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 2016; 4 (5): 361–371. DOI:10.1016/S2213-2600(16)30019-4.; Ghofrani H.A., D’Armini A.M., Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2013; 369 (4): 319–329. DOI:10.1056/NEJMoa1209657.; Simonneau G., D’Armini A.M., Ghofrani H.A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur. Respir. J. 2015; 45 (5): 1293–1302. DOI:10.1183/09031936.00087114.; Simonneau G., D’Armini A.M., Ghofrani H.A. et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 2016; 4 (5): 372–380. DOI:10.1016/S2213-2600(16)30022-4.; https://journal.pulmonology.ru/pulm/article/view/948

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/948
https://doi.org/10.18093/0869-0189-2017-27-6-803-810

المؤلفون: Javed Butler, Muhammad Shariq Usman, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Justin A. Ezekowitz, Cecilia Freitas, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Giuseppe M.C. Rosano, Clara Inés Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad

المصدر: European journal of heart failureReferences.

مصطلحات موضوعية: Vericiguat, HFrEF, Soluble guanylate cyclase stimulators, Cardiology and Cardiovascular Medicine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8211571f54e5fc0595be61e91e0f5b25
https://pubmed.ncbi.nlm.nih.gov/36250238

المؤلفون: N. A. Tsareva, Н. А. Царева

المصدر: PULMONOLOGIYA; Том 27, № 2 (2017); 216-231 ; Пульмонология; Том 27, № 2 (2017); 216-231 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-27-2

مصطلحات موضوعية: селективные агонисты рецепторов простациклина.ajrccm/145.1.101, endothelin receptor antagonists, prostacyclins, soluble guanylate cyclase stimulators, phosphodiesterase 5 inhibitors, selective prostacyclin receptor agonists, антагонисты эндотелиновых рецепторов, простациклины, стимуляторы растворимой гуанилатциклазы, ингибиторы фосфодиэстеразы 5-го типа

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/846/712; Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34 (6): 1219–1263. DOI:10.1183/09031936.00139009.; Чазова И.Е., Мартынюк Т.В., ред. Легочная гипертензия. М.: Практика; 2015.; Vachiery J.-L., Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur. Respir. Rev. 2012; 21 (126): 313–320. DOI:10.1183/09059180.00005412.; Chemla D., Castelain V., Herve P. et al. Haemodynamic evaluation of pulmonary hypertension. Eur. Respir. J. 2002; 20 (5): 1314–1331. DOI:10.1183/09031936.02.00068002.; Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI:10.1161/CIRCULATIONAHA.109.898122.; Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54 (30): S55–S56. DOI:10.1016/j.jacc.2009.04.011.; Berger R.M., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012; 379 (9815): 537–546. DOI:10.1016/S0140-6736(11)61621-8.; Trulock E., Edwards L., Taylor D. et al. Registry of the International Society for Heart and Lung Transplantation twenty fourth official adult lung and heart lung transplantation report 2007. J. Heart Lung Transplant. 2007; 26 (8): 782–795. DOI:10.1016/j.healun.2007.06.003.; Stehlik J., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report–2010. J. Heart Lung Transplant. 2010; 29 (10): 1089– 1103. DOI:10.1016/j.healun.2010.08.007.; Sitbon O., Morrell N.W. Pathways in pulmonary arterial hypertension: the future is here. Eur. Respir. Rev. 2012; 21 (126): 321–327. DOI:10.1183/09059180.00004812.; Solomon J.J., Olson A.L., Fischer A. et al. Scleroderma lung disease. Eur. Respir. Rev. 2013; 22 (127): 6–19. DOI:10.1183/09059180.00005512.; Guazzi M., Galie N. Pulmonary hypertension in left heart disease. Eur. Respir. Rev. 2012; 21 (126): 338–346. DOI:10.1183/09059180.00004612.; Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112 (8): 828–835. DOI:10.1161/CIRCULATIONAHA.104.529800.; Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30 (1): 104–109. DOI:10.1183/09031936.00092306.; Galie N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J. 2010; 31 (1): 2080–2086. DOI:10.1093/eurheartj/ehq152.; Michelakis E.D. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. 2003; 8 (1): 5–21. DOI:10.1023/A:1022150819223.; Rubin L.J., Simonneau G., Badesch D. et al. The study of risk in pulmonary arterial hypertension. Eur. Respir. Rev. 2012; 21 (125): 234–238. DOI:10.1183/09059180.00003712.; Humbert M., Souza R., Galie N. et al. Pulmonary arterial hypertension: bridging the present to the future. Eur. Respir. Rev. 2012; 21 (126): 267–270. DOI:10.1183/09059180.00005312.; Simonneau G., Gatzolis G., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D35–D41. DOI:10.1016/j.jacc.2013.10.029.; Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur. Respir. J. 2010; 36 (3): 549–555. DOI:10.1183/09031936.00057010.; Galie N., Hoeper M., Torbicki A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009; 30 (20): 2493– 2537. DOI:10.1093/eurheartj/ehr046.; Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2012; 39 (3): 589–596. DOI:10.1183/09031936.00092311.; Soubrier F., Chung W.K., Machado R. et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D13–D21. DOI:10.1016/j.jacc.2013.10.035.; Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat. Genet. 2014; 46 (1): 65–69. DOI:10.1038/ng.2844.; D’Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 2012; 21(126): 328–337. DOI:10.1183/09059180.00004712.; Huang J.B., Liang J., Zhou L.Y. Eisenmenger Syndrome: Not Always Inoperable. Respir. Care. 2012; 57 (9): 1488–1495. DOI:10.4187/respcare.01418.; Rubin L.J. Primary pulmonary hypertension. Chest. 1993; 104 (1): 236–250.; Rubin L.J., Badesch D.B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 2005; 143 (4): 282–292. DOI:10.7326/0003-4819-143-4200508160-00009.; Galie N., Rubin L.J. Introduction: new insights into a challenging disease: A review of the third world symposium on pulmonary arterial hypertension. Am. Coll. Cardiol. J. 2004; 43 (12): S1. DOI:10.1016/j.jacc.2004.03.003.; Galie N., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (24): 2243–2278. DOI:10.1016/j.ehj.2004.09.014.; Hambly N., Alawfi F., Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016; 188 (11): 804–812. DOI:10.1503/cmaj.151075.; McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/ AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119 (16): 2250–2294. DOI:10.1161/CIRCULATIONAHA.109.192230.; Чазова И.Е., Жданов В.С., Веселова С.П., Мареев В.Ю. Патология первичной легочной гипертензии. Архив патологии. 1993; (3): 52–55.0; Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J. Am. Coll. Cardiol. 2011; 58 (5): 538–546. DOI:10.1016/j.jacc.2011.03.033.; Raymond R.J., Hinderliter A.L., Willis P.W. et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2002; 39 (7): 1214–1219.; Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122 (2): 156–163. DOI:10.1161/CIRCULATIONAHA.109.911818.; Stenmark K.R., Davie N., Frid M. et al. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda). 2006; 21 (2): 134–145. DOI:10.1152/physiol.00053.2005.; Tuber R.M., Cool C.D., Yeager M. et al. The pathobiology of pulmonary hypertension. Endothelium. Clin. Chest Med. 2001; 22 (3): 405–418.; Gossage J.R., Christman B.W. Mediators of acute and chronic pulmonary hypertension. Semin. Respir. Crit. Care Med. 1994; 15 (4): 453–462.; Galie N., Manes A., Branzi A. New insights on pulmonary arterial hypertension. Rev. Esp. Cardiol. 2004; 57 (7): 603– 607. DOI:10.1016/S1885-5857(06)60282-X.; Duong-Quy S. Physiopathology of pulmonary hypertension: from bio-molecular mechanism to target treatment. J. Vasc. Med. Surg. 2016; 22 (4): 294–299. DOI:10.4172/2329-6925.1000294.; Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104 (3): 342–345. DOI:10.1161/01.CIR.104.3.342.; Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43 (12, Suppl.): S40–S47. DOI:10.1016/j.jacc.2004.02.032.; McGoon M.D. The assessment of pulmonary hypertension. Clin. Chest Med. 2001; 22 (3): 493–508.; McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation. 2006; 114 (13): 1417–1431. DOI:10.1161/CIRCULATIONAHA.104.503540.; Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J. 2013; 42 (6): 1575–1585. DOI:10.1183/09031936.00184412.; Sun X.G., Hansen J.E., Oudiz R.J., Wasserman K. Pulmonary function in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2003; 41 (6): 1028–1035. DOI:10.1016/S0735-1097(02)02964-9.; Чазова И.Е., Мартынюк Т.В., Авдеев С.Н. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив. 2014; 86 (9): 4–23. DOI: terapevticheskij-arkhiv/2014/9/030040-3660201491.; Rudski L.G., Lai W.W., Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echo- cardiogr. 2010; 23 (7): 685–713. DOI:10.1016/j.echo.2010.05.010.; Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015; 28 (1): 1–39. DOI:10.1016/j.echo.2014.10.003.; Lang I., Madani M. Update on Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2014; 130 (6): 508– 518. DOI:10.1161/CIRCULATIONAHA.114.009309.; Rajaram S., Swift A.J., Telfer A. et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013; 68 (7): 677–678. DOI: org/10.1136/thoraxjnl-2012-203020.; Sitbon O., Badesch D., Channick R. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003; 124 (1): 247–254. DOI:10.1378/chest.124.1-suppl.247S.; Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001; 358 (9288): 1119–1123. DOI:10.1016/S0140-6736(01)06250-X.; Galie N., Rubin L., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet. 2008; 371 (2930): 2093–2100. DOI:10.1016/S0140-6736(08)60919-8.; Savarese G., Paolillo S., Costanzo P. et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. JACC. 2012; 60 (13): 1192–1201. DOI:10.1016/j.jacc.2012.01.083.; Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999; 99 (9): 1197–1208. DOI:10.1161/01.CIR.99.9.1197.; Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin. Chest Med. 2007; 28 (1): 117–125.; Мартынюк Т.В., Архипова О.А., Кобаль Е.А. и др. Применение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гипертензией: первый российский опыт и взгляд в будущее. Системные гипертензии. 2011; 8 (4): 51–56.; Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2006; 27 (5): 589–595. DOI:10.1093/eurheartj/ehi728.; Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты 1-годичного исследования. Терапевтический архив. 2013; 85 (3): 38–43.; Rubin L., Badesch M., Barst R. et al. Randomized trial of endothelin antagonist therapy. N. Engl. J. Med. 2002; 346 (12): 896–903. DOI:10.1056/NEJMoa012212.; Galie N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010–3019. DOI:10.1161/CIRCULATIONAHA.107.742510.; Oudiz R.J., Galie N., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 52 (21): 1971–1981. DOI:10.1016/j.jacc.2009.07.033.; Badesch D.B., Feldman J., Keogh A. et al. ARIES3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc. Ther. 2012; 30 (2): 93–99. DOI:10.1111/j.1755-5922.2011.00279.x.; Pulido T., Adzerikho I., Channick R.N. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369 (9): 809–818. DOI:10.1056/NEJMoa1213917.; Galie N., Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J. Am. Coll. Cardiol. 2013; 62 (12): 1101–1102. DOI:10.1016/j.jacc.2013.06.032.; Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 1990; 112 (7): 485–491.; Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [see comments]. N. Engl. J. Med. 1996; 334 (5): 296–302. DOI:10.1056/NEJM199602013340504.; Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40 (4): 780–788. DOI:10.1016/S0735-1097(02)02012-0.; McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477–1482. DOI:10.1161/01.CIR.0000029100.82385.58.; Sitbon O., Delcroix M., Bergot E. et al. EPITOME-2: an openlabel study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am. Heart J. 2014; 167 (2): 210–217. DOI:10.1016/j.ahj.2013.08.007.; Galie N., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension. Am. J. Respir. Med. 2003; 2 (2): 123–137.; Simonneau G., Barst R.J., Galie N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165 (6): 800–804. DOI:10.1164/ajrccm.165.6.2106079.; Hiremath J., Thanikachalam S., Parikh K. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J. Heart Lung Transplant. 2010; 29 (2): 137–149. DOI:10.1016/j.healun.2009.09.005.; Tapson V.F., Gomberg-Maitland M., McLaughlin V.V. et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006; 129 (3): 683–688. DOI:10.1378/chest.129.3.683.; Barst R.J., McGoon M., McLaughlin V.V. et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 41 (12): 2119–2125. DOI:10.1016/S0735-1097(03)00463-7.; Olschewski H., Simommeau G., Galie N. et al. Inhaled iloprost in severe pulmonary hypertension. N. Engl. Med. 2002; 347 (5): 322–329. DOI:10.1056/NEJMoa020204.; McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174 (11): 1257–1263. DOI:10.1164/rccm.200603-358OC.; Ghofrani H.A., Rose F., Schermuly R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 42 (1): 158–164. DOI:10.1016/S0735-1097(03)00555-2.; Michelakis E., Tymchak W., Lien D. et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002; 105 (20): 2398–2403. DOI:10.1161/01.CIR.0000016641.12984.DC.; Evgenov O.V., Pacher P., Schmidt P.M. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 2006; 5 (9): 755–768. DOI:10.1038/nrd2038.; Schermuly R.T., Stasch J.P., Pullamsetti S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 2008; 32 (4): 881–891. DOI:10.1183/09031936.00114407.; Stasch J.P., Evgenov O.V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 2013; 218 (1): 279–313. DOI:10.1007/978-3-642-38664-0-12.; Ghofrani H.A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur. Respir. Rev. 2009; 18 (111): 35–41. DOI:10.1183/09059180.00011112.; Stasch J.P., Hobbs A. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 2009; (191): 277–308. DOI:10.1007/978-3-540-68964-5-13.; Ghofrani H.A., Galie N., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369 (4): 330–340. DOI:10.1056/NEJMoa1209655.; Ghofrani H.A., D'Armini A., Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2013; 369 (4): 319–329. DOI:10.1056/NEJMoa1209657.; Царева Н.А., Авдеев С.Н., Неклюдова Г.В. Последовательная комбинированная терапия у больной идиопатической легочной артериальной гипертензией. Кардиология. 2016; 56 (3): 97–100. DOI:10.18565/cardio.2016.3.97-100.; McLaughlin V.V., Channik R., Chin K.M. et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J. Am. Coll. Cardiol. 2015; 65 (10): 1538–1588. DOI:10.1016/S0735-1097(15)61538-8.; https://journal.pulmonology.ru/pulm/article/view/846

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/846
https://doi.org/10.18093/0869-0189-2017-27-2-216-231

المؤلفون: Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M, Badagliacca, Roberto, Berger, Rolf M F, Brida, Margarita, Carlsen, Jørn, Coats, Andrew J S, Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S, Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G, Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M, Pepke-Zaba, Joanna, Quint, Jennifer K, RÃ¥degran, Göran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean Luc, Vonk Noordegraaf, Anton, Delcroix, Marion, Rosenkranz, Stephan, ESC/ERS Scientific Document Group

المساهمون: Beghetti, Maurice

المصدر: ISSN: 0195-668X ; European heart journal, vol. 43, no. 38 (2022) p. 3618-3731.

مصطلحات موضوعية: info:eu-repo/classification/ddc/618, Balloon pulmonary angioplasty, Chronic thrombo-embolic pulmonary hypertension, Congenital heart disease, Connective tissue disease, Endothelin receptor antagonists, Guidelines, Left heart disease, Lung disease, Lung transplantation, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Prostacyclin receptor agonists, Pulmonary arterial hypertension, Pulmonary endarterectomy, Pulmonary hypertension, Soluble guanylate cyclase stimulators, Humans, Hypertension, Pulmonary / diagnosis, Pulmonary / therapy

Relation: info:eu-repo/semantics/altIdentifier/pmid/36017548; https://archive-ouverte.unige.ch/unige:174479; unige:174479

الاتاحة: https://archive-ouverte.unige.ch/unige:174479

المؤلفون: Xiao-Yan Jia, Yong-Ming Liu, Yong-Fei Wang, Jin-Yang An, Ke-Ling Peng, Hua Wang

مصطلحات موضوعية: Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, cardiovascular research, CiteSpace, bibliometrics, heart failure, soluble guanylate cyclase stimulators, web of science, VOSviewer

Relation: https://figshare.com/articles/dataset/DataSheet1_Bibliometric_study_of_soluble_guanylate_cyclase_stimulators_in_cardiovascular_research_based_on_web_of_science_from_1992_to_2021_ZIP/20548503

الاتاحة: https://doi.org/10.3389/fphar.2022.963255.s001
https://figshare.com/articles/dataset/DataSheet1_Bibliometric_study_of_soluble_guanylate_cyclase_stimulators_in_cardiovascular_research_based_on_web_of_science_from_1992_to_2021_ZIP/20548503